摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Boc-Glu(Bzl)-OBt | 104706-58-3

中文名称
——
中文别名
——
英文名称
Boc-Glu(Bzl)-OBt
英文别名
1-O-(benzotriazol-1-yl) 5-O-benzyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanedioate
Boc-Glu(Bzl)-OBt化学式
CAS
104706-58-3
化学式
C23H26N4O6
mdl
——
分子量
454.483
InChiKey
BIQCLZVNIOIQPN-SFHVURJKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.27±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    33.0
  • 可旋转键数:
    8.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    121.64
  • 氢给体数:
    1.0
  • 氢受体数:
    9.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis of the octadecapeptide corresponding to positions 32 to 49 of the revised amino acid sequence of thymopoietin II and its effect on low E-rosette forming cells of an aged patient with chronic renal failure.
    作者:TAKASHI ABIKO、HIROSHI SEKINO
    DOI:10.1248/cpb.30.3271
    日期:——
    The octadecapeptide, H-Arg-Lys-Asp-Val-Tyr-Val-Glu-Leu-Tyr-Leu-Gln-Ser-Leu-Thr-Ala-Leu-Lys-Arg-OH, corresponding to positions 32 to 49 of the revised amino acid sequence of bovine thymopoietin II was synthesized by the azide condensation of three fragments, (32-36), (37-41) and (42-49), followed by deprotection with hydrogen fluoride in the presence of anisole-thioanisole-o-cresol. The in vitro addition of the synthetic thymopoietin II (32-49) significantly restored the low E-rosette forming capacity of cells from an aged patient with chronic renal failure to normal levels. The in vitro effect of [Gln38, Thr43, Val47]-thymopoietin II (32-49) on the low E-rosette forming capacity of cells from the aged patient with chronic renal failure was also compared with that of the synthetic thymopoietin II (32-49). The [Gln38, Thr43, Val47]-thymopoietin II (32-49) was approximately equipotent with the synthetic thymopoietin II (32-49) at a concentration of 100 μg/ml.
    十八肽H-Arg-Lys-Asp-Val-Tyr-Val-Glu-Leu-Tyr-Leu-Gln-Ser-Leu-Thr-Ala-Leu-Lys-Arg-OH,对应于牛胸腺生成素II修订后的氨基酸序列的第32至49位,通过三个片段(32-36)、(37-41)和(42-49)的叠氮化物缩合合成,随后在茴香硫醚-邻甲酚存在下用氢氟酸脱保护。体外添加合成的胸腺生成素II(32-49)显著恢复了来自慢性肾衰竭老年患者的细胞的低E玫瑰花形成能力至正常平。[Gln38, Thr43, Val47]胸腺生成素II(32-49)对来自慢性肾衰竭老年患者的细胞的低E玫瑰花形成能力的影响也与合成的胸腺生成素II(32-49)进行了比较。在100 μg/ml的浓度下,[Gln38, Thr43, Val47]胸腺生成素II(32-49)与合成的胸腺生成素II(32-49)大致等效。
  • A 12-Porphyrin System: Syntheses of Peptide Porphyrins with Multiple Histidines and the Aggregation Behavior in the Presence of Hemin
    作者:Masato Ushiyama、Atsushi Yoshino、Takeshi Yamamura、Yasuo Shida、Fumio Arisaka
    DOI:10.1246/bcsj.72.1351
    日期:1999.6
    We succeeded in combining multiple-histidine peptides with porphyrins; that is to say, we synthesized three peptide porphyrins consisting of α4-meso-tetrakis(o-aminophenyl)porphyrin, α4-H2TAPP, and amphiphilic peptide, α4-(PepA18)n(AG)4−n-H2TAPP (n = 1, 3, and 4; PepA18 = EEALEKHEKALEKHEKAG), in the liquid phase. These compounds were designed to construct multiple porphyrin systems; in other words, each peptide attached on the H2TAPP was designed to contain two histidines. The stability of the porphyrins, (AG)4-H2TAPP and (AG)1(Boc-AG)3-H2TAPP, as well as the coupling conditions between the porphyrin fragments and the 16-residue peptide, EEALEKHEKALEKHEK, to give α4-(PepA18)n(AG)4−n-H2TAPP (n = 1, 3, and 4) were studied in detail with respect to the temperature, solvents, coupling reagents, additives, and amines. This search revealed that the combination of DMF/benzotriazol-1-yl-oxy-tris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP)/N,N-diisopropylethylamine is suitable for the purpose. The search also clarified that it is possible to synthesize α4-(PepA18)4-H2TAPP and α4-(PepA18)3(AG)1-H2TAPP selectively by choosing the coupling additives 1-hydroxy-7-azabenzotriazole (HOAt) and 1-hydroxybenzotriazole (HOBt), respectively.All of the compounds showed 40% helicity in a solution (phospate buffer, pH = 7.0) containing 2,2,2-trifluoroethanol (TFE). The UV-vis and circular-dichroism spectrophotometric titrations of Fe(III) protoporphyrin IX chloride, B, with α4-(PepA18)4-ZnTAPP, A, indicated that up to three equivalents of B were incorporated into A in a buffer solution containing 15% TFE. Sedimentation-equilibrium ultracentrifugation experiments showed that A is a dimer in the solution, and that this dimer is transformed to a trimer when B is incorporated into A. These results suggest that A achieves a 12-porphyrin system consisting of different kinds of metalloporphyrin.
    我们成功地将多组酸肽与卟啉结合,即在液相中合成了三种由α4-均四(邻基苯基)卟啉、α4-H2TAPP和两亲性肽组成的肽卟啉,α4-(PepA18)n(AG)4−n-H2TAPP(n=1,3,4;PepA18=EEALEKHEKALEKHEKAG)。这些化合物旨在构建多卟啉体系;换言之,每个附着在H2TAPP上的肽段设计为含有两个组酸。针对温度、溶剂、偶联试剂、添加剂和胺,详细研究了卟啉的稳定性,(AG)4-H2TAPP和(AG)1(Boc-AG)3-H2TAPP,以及卟啉片段与16残基肽,EEALEKHEKALEKHEK之间的耦合条件,以生成α4-(PepA18)n(AG)4−n-H2TAPP(n=1,3,4)。研究发现,DMF/苯并三唑-1-基氧基三(吡咯烷基)六氟磷酸盐(PyBOP)/N,N-二异丙基乙胺的组合适用于此目的。研究还阐明,通过选择偶联添加剂1-羟基-7-氮杂苯并三唑(HOAt)和1-羟基苯并三唑(HOBt),可以有选择性地合成α4-(PepA18)4-H2TAPP和α4-(PepA18)3(AG)1-H2TAPP。所有化合物在含有2,2,2-三氟乙醇(TFE)的溶液(磷酸盐缓冲液,pH=7.0)中均显示出40%的螺旋度。Fe(III)原卟啉IX化物B与α4-(PepA18)4-ZnTAPP,A的紫外-可见光和圆二色光谱滴定表明,在含有15% TFE的缓冲溶液中,最多可掺入三个当量的B到A中。沉降平衡超速离心实验显示,A在溶液中为二聚体,当B掺入A时,该二聚体转变为三聚体。这些结果表明,A实现了由不同卟啉组成的12卟啉体系。
  • Meldal, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1986, vol. 40, # 4, p. 242 - 249
    作者:Meldal
    DOI:——
    日期:——
  • Preparation of large macrocyclic peptides using the oxime resin
    作者:Jean-Philippe Blanchette、Patrick Ferland、Normand Voyer
    DOI:10.1016/j.tetlet.2007.05.033
    日期:2007.7
    We exploited a peptide cyclization-cleavage reaction on oxime resin (PCOR) to obtain in one key step large macrocyclic peptides. Herein, we report on the different parameters affecting the cyclization-oligomerization reaction, whether to favor cyclic monomer or cyclic oligomers formation. (c) 2007 Elsevier Ltd. All rights reserved.
  • (3S)-N-(l-Aminoacyl)-1,2,3,4-tetrahydroisoquinolines, a class of novel antithrombotic agents: Synthesis, bioassay, 3D QSAR, and ADME analysis
    作者:Meiqing Zheng、Xiaoyi Zhang、Ming Zhao、Heng Wei Chang、Wei Wang、Yuji Wang、Shiqi Peng
    DOI:10.1016/j.bmc.2008.09.019
    日期:2008.11
    To increase antithrombotic activity, 3S-tetrahydroisoquinoline-3-carboxylic acid (1) was modified with natural amino acids to form 19 novel dipeptide analogs, 3S-tetrahydroisoquinoline-3-carboxyamino acids (5a-s), targeting the intestinal peptide transport system. In vitro assay of 5a-s indicated that their potencies for inhibiting adenosine diphosphate (ADP), arachidonic acid (AA), platelet-activating factor (PAF), and thrombin (TH)-induced platelet aggregations were higher than that of 1. Additionally, in vivo assay of 5a-s indicated that their potencies for inhibiting thrombogenesis in rats were also higher than that of 1. Among the candidates, 5h with Ser attachment showed the most impressive features for further development. According to molecular field analysis based Cerius(2) QSAR module, two equations (r, 0.961 and 0.988) correlating the structures with both in vitro and in vivo activities of 5a-s were established. ADMET calculations predict higher intestinal absorption for compounds 5a-s. Further investigation with 5h as a lead compound is underway. (C) 2008 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸